Table 6.

Talks presented at the 2014 Asilomar conference ¹.

Session	Speaker	Title
Keynote	Alan Engelman	Integrase host cofactors: Unanticipated antiretroviral bedfellows *
1	Robert Craigie	Retroviral integrase: Activities and structure
	Michael Miller	Anti-IN inhibitors: Clinical experience and new drug development
2	Akram Alian	Another piece in the integrase multimerization puzzle: The first monomeric integrase core domain structure
	Duane Grandgenett	Structural biology of kinetically stabilized RSV and HIV-1 synaptic complexes produced with integrase strand transfer inhibitors
	Min Li	Outer integrase subunits in the intasome are dispensable for catalysis of integration and a “magic” peptide that enhances HIV-1 integrase *
	Mark Andrake	Multimerization properties of retroviral integrases
	Marc Ruff	The HIV-1 pre-integration complexes: Structure, function and dynamics
	Mamuka Kvaratskhelia	Structure and function of retroviral integrases as a therapeutic target
	Kellie Jurado	Characterization of HIV-1 particle maturation defect caused by allosteric integrase inhibitors (selected from abstracts)
	Samson Chow	Characterizing the interaction between HIV-1 IN and CA assemblies
3	Carlos Casiano	Beyond HIV-1 integration: Emerging roles of LEDGF/p75 in cancer and autoimmunity
	Anna Cereseto	3D analysis of retrovirus-nucleus interactions
	Ganjam Kalpana	An essential role of integrase binding protein INI1/hSNF5 in HIV-1 post-transcriptional mechanisms leading to assembly
	Eric Poeschla	TALEN knockout of the HIV-1 integration cofactor LEDGF/p75
	Anais Jaspart	Phosphorylation of HIV-1 integrase by GCN2 (selected from abstracts) *
4	Mark Underwood	HIV-1 primary and secondary integrase mutations: Dolutegravir clinical response, and effects on DTG, raltegravir (RAL), and elvitegravir (EVG) resistance and replication capacity *
	Yves Pommier	Novel INSTIs to overcome drug resistance mechanisms
	Zeger Debyser	Novel pleiotropic roles of HIV integrase revealed by LEDGINs and integrase polymorphisms
	Richard Benarous	Resistance analysis with HIV-1 integrase-LEDGF allosteric inhibitors that effect virion maturation but do not influence packaging of a functional RNA genome (selected from abstracts)
	Philippe Cotelle	2-Hydroxyisoquinoline—1,3(2H, 4H)—diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance
	Ira Dicker	A simple and accurate in vitro method for predicting serum protein binding of HIV integrase strand transfer inhibitors
	Nouri Neamati	Discovery of first-in-class inhibitors of HIV-1 integrase-HSP90 interaction
5	Marc Lavigne	Role of DNA and chromatin structure in HIV-1 integration
	Vincent Parissi	Regulation of retroviral integration by chromatin and intasome structures
	Stephen Hughes	Specific HIV integration sites are linked to the clonal expansion and persistence of infected cells in patients *
	Henry Levin	Analysis of 1-million independent HIV-1 integration sites identifies a link with mRNA splicing
	Monica J. Roth	MLV integration site selection
	Frederic Bushman	Retroviral DNA integration in human gene therapy
6	Suzanne Sandmeyer	Parsing the determinants of extreme integration specificity
	Karen Beemon	Targets of integration of ALV-J in chicken hemangiomas *
	Donald Kohn	Clinical applications of integrating vectors for gene therapy
	Emmanuelle Six	Tracking the dynamic of hematopoietic progenitors through integration site analysis in gene therapy trials
	Richard Gabriel	Integration of retroviral vectors in gene therapy—understanding and avoiding severe side effects
	Szilvia Solyom	Massive somatic L1 retrotransposition occurs early during gastrointestinal tumorigenesis

¹ Talks highlighted in main text denoted by *.